Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
South Korea Drug Review Innovation

Korea Seeks Fast Tracks For Innovative And Public Health Crisis Drugs

  • Analysis

Executive Summary

Korean pharma industry welcomes a bill that aims to establish fast-track review and approval system for innovative drugs and medicines used in public health crises.

You may also be interested in...



Korea 2018 Review: Hopes And Worries Coexist In Pharma Sector

As the year end approaches, Scrip wraps up what major events made headlines in the South Korean pharma/biotech sector in 2018.

US, Korea FTA Talks To Improve Pro-Innovation Pricing System

The US and South Korea's agreement to modify Korea's drug pricing system for innovative drugs raises concerns over an increased price burden for global drugs in the country.

Korea To Introduce Fast-Track Review For Cutting-Edge Biologics, Devices

South Korea is set to adopt fast-track review systems for cutting-edge biologics and medical devices late this year as it continues to nurture the biotech industry and in line with global trends

Table

View full table

Topics

Tags:
South Korea Drug Review Innovation
Latest Headlines

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

See All
UsernamePublicRestriction

Register

PS123991

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By